RESEARCH MONOGRAPH · KDC-MN-043

Centrophenoxine (Meclofenoxate)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

59/100

Old-school lipofuscin-clearance compound with surprisingly persistent interest from longevity researchers

Centrophenoxine has one of the more unusual mechanism stories on this list. It's a DMAE ester (specifically, p-chlorophenoxyacetic acid esterified to dimethylaminoethanol), originally developed by ANCA Laboratories in the 50s as Lucidril, and the headline claim was that it reduced accumulated lipofuscin in aged neurons. Thats either ridiculous or important depending on whether the lipofuscin hypothesis of aging matters, and the field has flipped on this question a few times.

The classical work from the 70s (Nandy and Bourne studies, then Hochschild's life-extension experiments in mice) showed real reductions in fluorescent lipofuscin deposits in aged neurons, and at least one mouse longevity experiment found a modest median lifespan extension. The interpretive issue is whether lipofuscin is causally driving anything or just a marker. We dont know the answer yet, and thats actually still an open question in geroscience.

The mechanism splits into the DMAE arm (cholinergic precursor of sorts, though the actual flux to ACh is debated) and the antioxidant component. Both have some preclinical support. The free radical scavenging in aged brain tissue is reproducible. The cholinergic angle is murkier.

What we like: genuinely unusual mechanism category, real preclinical longevity signal (small but reproducible), and the molecule has been in clinical use for cognitive impairment in Europe for decades, so safety data is reasonable.

What we dont like: the human cognitive data is mostly old, often poorly controlled, and the lipofuscin story is still mechanistically incomplete. Modern aging research has largely moved on from the lipofuscin hypothesis to mTOR and senescence pathways, which is fair enough.

Sourcing is reasonable. The molecule is commercially available from multiple European suppliers as both the hydrochloride and the free base, HPLC validation is established, and the stability profile is well-known (stable in dry form, hydrolyzes in solution).

For research, centrophenoxine is a useful tool if you're working aging models and care about lipofuscin or related autofluorescence markers. As a cognitive enhancer in its own right, the data isnt strong enough to recommend it on those grounds.

One of those compounds that refuses to die, and probably for reasons that arent fully understood yet.

Evidence: 50
Mechanism: 55
Reliability: 55
Safety: 70
Sourcing: 70
Value: 60
Signal: 55
Staying power: 55

Plain-language summary Intrigue 56 / 100

Centrophenoxine is an ester of DMAE that crosses into the brain to support cognitive function and remove lipofuscin (cellular waste pigment). Used historically for age-related cognitive decline. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

DMAE ester / lipofuscin-targeting cognitive enhancer

An ester of DMAE and 4-chlorophenoxyacetic acid developed in 1959, marketed in many countries for senile cognitive impairment with documented lipofuscin clearance activity.

Abstract

Centrophenoxine (Lucidril, Meclofenoxate; (2-dimethylaminoethyl) 4-chlorophenoxyacetate; CAS 51-68-3; molecular formula C12H16ClNO3; molecular weight 257.71) is an ester combining 2-dimethylaminoethanol (DMAE) and 4-chlorophenoxyacetic acid, developed in France in 1959. The compound is marketed in Italy, Hungary, France, and several other European countries for senile cognitive impairment, post-stroke recovery, and alcohol-related cognitive decline. The principal mechanism is dual: hepatic and central hydrolysis releases DMAE, which contributes to phosphatidylcholine synthesis, and 4-chlorophenoxyacetic acid, which has been shown to clear lipofuscin (the brown age-related pigment that accumulates in long-lived cells including neurons) through a mechanism that remains incompletely characterized. The lipofuscin-clearance phenotype is the compound's distinctive feature; aging neurons accumulate lipofuscin progressively, and centrophenoxine treatment reduces accumulation in animal models. The clinical evidence base in human cognitive impairment is modest but consistent. Pharmacokinetics: plasma half-life is short (under 1 hour for the parent ester); active metabolites persist longer. Reported research dose ranges in the literature span 600 to 1200 mg. The compound is sold as a research chemical in the United States.

Mechanism of action

Hydrolyzed to DMAE (cholinergic precursor) and 4-chlorophenoxyacetic acid (lipofuscin clearance). Dual cholinergic and anti-aging effects.

Reported research dose ranges

600 to 1200 mg, as reported research dose ranges in the literature.

References

Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. Age Ageing 1977.
Nandy K. Centrophenoxine: effects on aging mammalian brain. J Am Geriatr Soc 1978.
Zs-Nagy I. Pharmacology of centrophenoxine and clinical studies. Aging Clin Exp Res 1989.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-043

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Centrophenoxine (Meclofenoxate)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs